Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5% - Here's Why

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) rose 5% during trading on Wednesday . The company traded as high as $11.53 and last traded at $11.70. Approximately 157,599 shares traded hands during trading, a decline of 91% from the average daily volume of 1,748,339 shares. The stock had previously closed at $11.15.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Finally, Roth Capital began coverage on Capricor Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $31.00 target price for the company. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $35.50.

Capricor Therapeutics Trading Up 6.8%

The stock's 50-day moving average is $10.15 and its 200-day moving average is $13.03. The firm has a market capitalization of $602.02 million, a price-to-earnings ratio of -12.43 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. During the same quarter in the prior year, the company earned ($0.31) earnings per share. On average, equities research analysts anticipate that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAPR. Summit Investment Advisors Inc. grew its holdings in Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new stake in Capricor Therapeutics during the 4th quarter worth approximately $68,000. AlphaQuest LLC bought a new stake in Capricor Therapeutics during the 4th quarter worth approximately $78,000. Finally, New York State Common Retirement Fund grew its holdings in Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 5,000 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.